JSJames Stockley

James Stockley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Stockley has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Physiological Small Airways Dysfunction and the Bronchodilator Response in Adults With Asthma and Its Risk Factors: A Retrospective Analysis

    by Mohammed Almeshari, Nowaf Y Alobaidi, James Stockley, Robert Stockley, Prasad Nagakumar, Benjamin Paul Sutton, Elizabeth Sapey

    Background: Physiological evidence of small airways dysfunction (SAD) is present in some patients with asthma and is associated with poor disease control. It is unclear if this represents a distinct phenotype of asthma or if it is an early manifestation of the disease. The study aimed to evaluate SAD in asthma and its clinical associations. Methods: A retrospective analysis of routinely collected health data obtained from adults referred for routine spirometric assessment as part of their clinical management. The Maximal Mid-Expiratory Flow (MMEF) z-scores were used to assess the prevalence and association factors for SAD. Pre- and post-bronchodilator data of MMEF and FEV1 in patients with and without SAD or airflow obstruction (AO) were analysed. Results: A total of 1094 patients were included. 366 (33.5%) had evidence of SAD of whom 261 (71.3%) also had AO. Current smokers were at an increased risk of having SAD (OR: 2.05; 95% CI: 1.43– 2.93). 214 patients had Bronchodilator response (BDR) data with 157 (73.4%) demonstrating BDR for MMEF and 121 (56.5%) for FEV1. SAD at baseline was associated with a significant BDR for FEV1 (OR of 3.59 (95% CI: 1.77– 7.57)) and MMEF (OR of 2.89 (95% CI: 1.41– 5.95)). Males were less likely to have a positive BDR for MMEF than females (OR of 0.46; 95% CI: 0.24– 0.89). Conclusion: SAD is common in asthma and is related to the presence of AO, cigarette smoking and is associated with increased BDR for both FEV1 and MMEF. The assessment of SAD in routine clinical practice may help identify airway impairment early for the initiation of targeted therapies.


  • Open Access

    Small airways dysfunction: The importance of utilising Z-scores to define MMEF abnormalities in clinical practice

    by Mohammed A. Almeshari, Nowaf Y. Alobaidi, Elizabeth Sapey, Robert A. Stockley, James A. Stockley


  • Open Access

    Small airway function measured using forced expiratory flow between 25% and 75% of vital capacity and its relationship to airflow limitation in symptomatic ever-smokers: a cross-sectional study

    by Nowaf Y Alobaidi, Mohammed Almeshari, James Stockley, Robert Andrew Stockley, Elizabeth Sapey

    Background: Chronic obstructive pulmonary disease (COPD) is diagnosed and its severity graded by traditional spirometric parameters (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) and FEV1, respectively) but these parameters are considered insensitive for identifying early pathology. Measures of small airway function, including forced expiratory flow between 25% and 75% of vital capacity (FEF25-75), may be more valuable in the earliest phases of COPD. This study aimed to determine the prevalence of low FEF25-75 in ever-smokers with and without airflow limitation (AL) and to determine whether FEF25-75 relates to AL severity. Method: A retrospective analysis of lung function data of 1458 ever-smokers suspected clinically of having COPD. Low FEF25-75 was defined by z-score<−0.8345 and AL was defined by FEV1/FVC z-scores<−1.645. The severity of AL was evaluated using FEV1 z-scores. Participants were placed into three groups: normal FEF25-75/ no AL (normal FEF25-75/AL−); low FEF25-75/ no AL (low FEF25-75/AL−) and low FEF25-75/ AL (low FEF25-75/AL+). Results: Low FEF25-75 was present in 99.9% of patients with AL, and 50% of those without AL. Patients in the low FEF25-75/AL− group had lower spirometric measures (including FEV1 FEF25-75/FVC and FEV3/FVC) than those in the normal FEF25-75/AL− group. FEF25-75 decreased with AL severity. A logistic regression model demonstrated that in the absence of AL, the presence of low FEF25-75 was associated with lower FEV1 and FEV1/FVC even when smoking history was accounted for. Conclusions: Low FEF25-75 is a physiological trait in patients with conventional spirometric AL and likely reflects early evidence of impairment in the small airways when spirometry is within the ‘normal range’. FEF25-75 likely identifies a group of patients with early evidence of pathological lung damage who warrant careful monitoring and reinforced early intervention to abrogate further lung injury.


  • Open Access

    COVID-19-related changes in outpatient CPAP setup pathways for OSA are linked with decreased 30-day CPAP usage

    by Chris D Turnbull, Martin Allen, Jennifer Appleby, Richard Brown, Nathalie Bryan, Ann Cooper, Brendan G Cooper, Cathie Gillooly, James Davidson, Hannah Farley, et al.

    The COVID-19 pandemic changed continuous positive airway pressure (CPAP) setup pathways. We evaluated patients commenced on CPAP in 2019 (prepandemic) and 2020 (post-first UK wave). Face-to-face (F2F) setup numbers, with CPAP turned on, decreased from 613 patients (98.9%) in 2019, to 6 (1.1%) in 2020. In 2020, setups were F2F without CPAP turned on (403 (71.1%)), or remote (158 (27.9%)). Prepandemic median CPAP usage at first follow-up was 5.4 (2.7–6.9) hours/night and fell by 0.9 hours/night (95% CI 0.5 to 1.2, p<0.0001) in 2020. We found clinically relevant reductions in CPAP usage with pathway changes post-COVID-19.


  • Open Access

    Small Airways Response to Bronchodilators in Adults with Asthma or COPD: A Systematic Review

    by Mohammed A Almeshari, Nowaf Y Alobaidi, Elizabeth Sapey, Omar Usmani, Robert A Stockley, James A Stockley

    Background: Bronchodilator responsiveness (BDR) is commonly used in the diagnosis of lung disease. Although small airways dysfunction is a feature of asthma and COPD, physiological tests of small airways are not included in guidelines for BDR testing. This systematic review assessed the current evidence of BDR using small airways function in asthma and COPD. Methods: The systematic review used standard methodology with the protocol prospectively registered on PROSPERO (CRD42020164140). Electronic medical databases (EMBASE and Medline) were searched using related keywords. Abstracts and full texts were screened independently by two reviewers. Studies that reported the change of physiological small airways function and FEV1 were included in the review. The revised Cochrane risk of bias tool for RCT and NIH quality assessment tool for cohort and cross-sectional studies were used to evaluate the studies. Results: A total of 934 articles were identified, with 12 meeting the inclusion criteria. Ten studies included asthma patients, 1 study included COPD patients and 1 study included both asthma and COPD. A total of 1104 participants were included, of whom 941 were asthmatic, 64 had COPD and 109 were healthy controls. Studies were heterogeneous in design including the device, dose and time intervals for BDR assessment. A small airway BDR was seen for most tests in asthma and COPD, including oscillometry (R5-20, reactance (X5), area of reactance (AX) and resonant frequency (Fres)) and Maximal Mid Expiratory Flow. Conclusion: There is a measurable BDR in the small airways. However, with no consensus on how to assess BDR, studies were heterogeneous. Further research is needed to inform how BDR should be assessed, its clinical impact and place in routine clinical practice.


  • Open Access

    Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 Clinics

    by James A. Stockley, Eyas A. Alhuthail, Andrew M. Coney, Dhruv Parekh, Tarekegn Geberhiwot, Nandan Gautum, Shyam C. Madathil, Brendan G. Cooper

    Introduction: There is relatively little published on the effects of COVID-19 on respiratory physiology, particularly breathing patterns. We sought to determine if there were lasting detrimental effect following hospital discharge and if these related to the severity of COVID-19.Methods: We reviewed lung function and breathing patterns in COVID-19 survivors > 3 months after discharge, comparing patients who had been admitted to the intensive therapy unit (ITU) (n = 47) to those who just received ward treatments (n = 45). Lung function included spirometry and gas transfer and breathing patterns were measured with structured light plethysmography. Continuous data were compared with an independent t-test or Mann Whitney-U test (depending on distribution) and nominal data were compared using a Fisher’s exact test (for 2 categories in 2 groups) or a chi-squared test (for > 2 categories in 2 groups). A p-value of < 0.05 was taken to be statistically significant.Results: We found evidence of pulmonary restriction (reduced vital capacity and/or alveolar volume) in 65.4% of all patients. 36.1% of all patients has a reduced transfer factor (TLCO) but the majority of these (78.1%) had a preserved/increased transfer coefficient (KCO), suggesting an extrapulmonary cause. There were no major differences between ITU and ward lung function, although KCOalone was higher in the ITU patients (p = 0.03). This could be explained partly by obesity, respiratory muscle fatigue, localised microvascular changes, or haemosiderosis from lung damage. Abnormal breathing patterns were observed in 18.8% of subjects, although no consistent pattern of breathing pattern abnormalities was evident.Conclusions: An “extrapulmonary restrictive” like pattern appears to be a common phenomenon in previously admitted COVID-19 survivors. Whilst the cause of this is not clear, the effects seem to be similar on patients whether or not they received mechanical ventilation or had ward based respiratory support/supplemental oxygen.


  • Open Access

    Lung Function and Breathing Patterns in Hospitalised COVID-19 Survivors: a Review of Post-COVID-19 Clinics

    by James Stockley, Eyas A Alhuthail, Andrew M Coney, Dhruv Parekh, Tarekegn Geberhiwot, Nandan Gautam, Shyam Madathil, Brendan Cooper

    Introduction: There is relatively little published on the effects of COVID-19 on respiratory physiology, particularly breathing patterns. We sought to determine if there were lasting detrimental effect following hospital discharge and if these related to the severity of COVID-19.Methods: We reviewed lung function and breathing patterns in COVID-19 survivors >3 months after discharge, comparing patients who had been admitted to the intensive therapy unit (ITU) (n=47) to those who just received ward treatments (n=45). Lung function included spirometry and gas transfer and breathing patterns were measured with structured light plethysmography. Continuous data were compared with an independent t-test or Mann Whitney-U test (depending on distribution) and nominal data were compared using a Fisher’s exact test (for 2 categories in 2 groups) or a chi-squared test (for >2 categories in 2 groups). A p-value of < 0.05 was taken to be statistically significant.Results: We found evidence of pulmonary restriction (reduced vital capacity and/or alveolar volume) in 65.4% of all patients. 36.1% of all patients has a reduced transfer factor (TLCO) but the majority of these (78.1%) had a preserved/increased transfer coefficient (KCO), suggesting an extrapulmonary cause. There were no major differences between ITU and ward lung function although KCO alone was higher in the ITU patients (p = 0.03). This could be explained partly by obesity, respiratory muscle fatigue, localised microvascular changes, or haemosiderosis from lung damage. Abnormal breathing patterns were observed in 18.8% of subjects, although no consistent pattern of breathing pattern abnormalities was evident.Conclusions: An “extrapulmonary restrictive” like pattern appears to be a common phenomenon in previously admitted COVID-19 survivors. Whilst the cause of this is not clear, the effects seem to be similar on patients whether or not they received mechanical ventilation or had ward based respiratory support/supplemental oxygen.

  • Open Access

    There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements

    by James A Stockley, Robert A Stockley, Elizabeth Sapey

    Background: It is known that lung function decline in Alpha-1 Antitrypsin Deficiency (AATD) varies. Those with a rapid decline are at highest risk of poorer outcomes but may benefit most from targeted treatments including augmentation therapy. Current evidence suggests rapid decliners can be identified after 3 years of serial follow-up. It would be advantageous to identify these patients over a shorter time period, especially in mild disease. Methods: Post-bronchodilator spirometry was performed every 6 months for a total of 18 months (4 measurements) by PiZZ AATD patients (ex- or never-smokers) either without spirometric COPD or with mild COPD. Where possible, retrospective spirometry data were included. Decline was assessed using 2 (baseline and 6 month) or four measurements (including baseline, 6, 12 and 18 months) and compared to retrospective decline rates using annual measurements over 3 years. Results: Seventy-two PiZZ AATD patients were included, with 27 having at least three years of retrospective, annual spirometry. 18-month progression obtained by linear regression showed variable degrees of change with 29 showing no decline, 8 showing slow decline and 35 showing rapid decline. Bland-Altman plots showed that there was no overall agreement between predicted rate of decline using data obtained over 6 months and that obtained over 18 months. Furthermore, there was no agreement between rate of decline from either 6 or 18 months’ data when compared to data collected over 3 years. The positive predictive value for rapid decline with 18 months of data compared to 3 years was only 50.0%. Conclusion: This study suggests serial lung function over 18 months cannot identify AATD patients who have rapidly declining lung function. There is an urgent need for different biomarkers to help identify these patients at the earliest opportunity.


  • Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency

    by James Stockley, Diana Crossley, Robert Stockley, Elizabeth Sapey

    Rationale: Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disease that can lead to the emphysema. Evidence suggests that small airways (SA) disease precedes emphysema. We compared traditional lung function and SA tests to CT evidence of emphysema in AATD subjects with mild or no COPD. Methods: 70 non-smokers with severe (PiZZ) AATD underwent lung function testing and high resolution CT (HRCT) scan. They were categorised based on HRCT data (Gevenois, P.A., et al. ERJ 1995; 5: 843–848); No emphysema (PD15 > -910HU, n=16), microscopic emphysema (PD15 -950 to -910HU, n=48) and macroscopic emphysema (PD15 < -950HU, n=6). Spirometry parameters (FEV1, FEV1/FVC, MMEF and Area Under the Expiratory Curve standardised for FVC (AEx/FVC)), Lung Clearance Index (LCI), Impulse Oscillometry (R5-R20), and Kco were compared across groups using a Kruskal-Wallis test. Results: There was progressively worsening lung function from no emphysema to microscopic and macroscopic emphysema observed for all parameters except R5-R20. Comparisons of FEV1/FVC, MMEF, AEx/FVC, LCI and Kco reached statistical significance (Table 1). Conclusions: There is a natural progression in traditional and SA lung function tests with the development of emphysema in AATD. The data suggest that monitoring lung function can detect deterioration before COPD and macroscopic emphysema becomes established. THIS RESEARCH IS FUNDED BY THE ALPHA-1 FOUNDATION